Clinical Trials e-Newsletter

Clinical Trials e-Newsletter | September 2019

Increasing African American Participation

in Clinical Trials

PHEN and Partners Address Strategies to Increase African American Participation in Clinical Trials

At PHEN's 15th Annual Summit, Gerren Wilson (Genentech), Sandra Amaro (Pfizer), Adrelia Allen (Merck) and Jovonni Spinner (FDA) joined Keith Crawford (PHEN) to discuss strategies to address the challenge of increasing diversity in clinical trials. Each outlined their respective approach to closing the prostate cancer disparity gap. Approaches ranged from improving cross-cultural competency within their organizations to broadening community outreach efforts. All agreed with the message echoed by Jovonni Spinner of the FDA, “we need people who will be using the products to be part of these trials .”

A complete video of this session is available below.

Summit 2019: Increasing African American Participation in Clinical Trial

Clinical Trials Update

PROTEUS Trial

The PROTEUS Trial is enrolling patients with advanced prostate cancer, who are candidates for radical prostatectomy.

This trial will study a drug to prevent reoccurrence of cancer after the prostate has been removed.

Patient Summary

MAGNITUDE Trial

The MAGNITUDE trial will compare a combination of an investigational medicine plus standard treatment, to a combination of a placebo plus standard treatment for men with metastatic prostate cancer to determine which is most effective. All men will receive the current standard of care treatment.

Patient Summary

Find A Trial That Fits

Your Needs

Click on the link below that defines where you are on your prostate cancer journey and PHEN's "Find Your Trial (FYT) Tool" will present you with a listing of available clinical trials.

Patients with Low and Intermediate Risk Prostate Cancer

High Risk Prostate Cancer Patients

Patients Treated with Prostatectomy or Radiation

Patients with Recurrent Prostate Cancer

Patients with Castration Resistant Prostate Cancer (CRPC)

Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients

Understanding Castration Resistant Prostate Cancer

Androgen deprivation (hormone) therapy, such as Lupron, works to reduce testosterone in the body to castration levels to prevent or slow the progression of prostate cancer.

What is Castration resistant Prostate Cancer?

Prostate cancer becomes Castration Resistant when the cancer progresses despite treatment with anti-androgen therapy.

What is non-Metastatic Castration Resistant Prostate Cancer?

Castration Resistant Prostate Cancer where no metastases have been detected.

What is Metastatic Castration Resistant Prostate Cancer?

Castration Resistant Prostate Cancer that has spread and metastasized to other parts of the body such as bones and other organs.